EP3057580
Lyfjaskammtaform sem innihalda natríum-1-[6-(morfólín-4-ýl)pýrimídín-4-ýl]-4-(1H-1,2,3-tríasól-1-ýl)-1H-pýrasól-5-ólat
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
13.10.2014EP published:
24.2.2021EP application number:
14783642.3
EP translation filed:
5.5.2021Grant published:
15.9.2021EPO information:
European Patent Register
Max expiry date:
12.10.2034Expiry date:
12.10.2025Next due date:
31.10.2025
Title:
PHARMACEUTICAL DOSAGE FORMS CONTAINING SODIUM-1-[6-(MORPHOLIN-4-YL)PYRIMIDIN-4-YL]-4-(1H-1,2,3-TRIAZOL-1-YL)-1H-PYRAZOL-5-OLATE
Timeline
Today
13.10.2014EP application
24.2.2021EP Publication
5.5.2021Translation submitted
15.9.2021Registration published
12.10.2025Expires
Owner
Name:
Bayer Pharma AktiengesellschaftAddress:
Müllerstrasse 178, 13353 Berlin, DE
Inventor
Name:
NEUMANN, HeikeAddress:
42117 Wuppertal, DE
Name:
BENKE, KlausAddress:
51465 Bergisch Gladbach, DE
Name:
FORMELL, MichaelAddress:
16548 Glienicke, DE
Name:
WINTER, GabrieleAddress:
16548 Glienicke, DE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
13189145Date:
17.10.2013Country:
EP
Classification
Categories:
A61K 9/20, A61K 9/28, A61K 31/5377, A61P 9/04, A61P 13/12, A61P 7/06
Annual fees
Number
Paid
Expires
Payer
Number: 8
Paid: 27.9.2021
Expires: 12.10.2022
Payer: Árnason Faktor ehf.
Number: 9
Paid: 27.9.2022
Expires: 12.10.2023
Payer: Árnason Faktor ehf.
Number: 10
Paid: 11.10.2023
Expires: 12.10.2024
Payer: Árnason Faktor ehf.
Number: 11
Paid: 23.9.2024
Expires: 12.10.2025
Payer: Árnason Faktor ehf.